Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
BACK ISSUE articles are $15 each.
International credit cards NOT accepted.

JCOM Paid Subscribers
user name:
Forgot password?

JCOM Abstract

J Clin Outcomes Manage 
2007 Apr;14(4):195-204
Sumatriptan/Naproxen sodium as early intervention for migraine: effects on functional ability, productivity, and satisfaction in 2 randomized controlled trials
Taylor FR, Heiring JO, Messina E, Braverman-Panza J, Ames MH, Byrd SC, McDonald SA, Burch SP

Abstract Objective: To examine the effects of early intervention with sumatriptan/naproxen sodium for migraine on functional ability, productivity, and patient satisfaction. Design: 2 randomized, double-blind, parallel-group studies. Participants and setting: Migraineurs aged 18 to 65 years at 106 U.S. neurology and headache clinics treated with sumatriptan 85 mg formulated with RT technology/naproxen sodium 500 mg or placebo within 1 hour of pain onset. Measurements: Functional ability on a 5-point scale through 4 hours postdose, migraine-associated disability time through 24 hours postdose, and satisfaction on the Revised Patient Perception of Migraine Questionnaire (PPMQ-R). Results: Two and 4 hours postdose, approximately twice as many patients reported normal functional ability with sumatriptan/naproxen than placebo in each study (P < 0.001). Total disability time was 47% to 48% lower with sumatriptan/naproxen than placebo (2.7 versus 5.1 hours study 1; 2.7 versus 5.2 hours study 2; P < 0.001). Mean lost workplace productivity and lost nonworkplace activity time were lower with sumatriptan/naproxen than placebo (lost workplace productivity: 1.8 versus 3.1 hours study 1 [P < 0.001]; 1.7 versus 2.5 hours study 2 [P < 0.05]; lost nonworkplace activity time: 2.2 versus 4.1 hours study 1; 2.2 versus 4.3 hours study 2 [P < 0.001]). Mean satisfaction scores were significantly higher with sumatriptan/naproxen versus placebo for the efficacy, functionality, and ease of use subscales and the total score in both studies. Conclusion: Sumatriptan/naproxen confers rapid, restoration of functional ability and productivity in migraine and receives high patient satisfaction ratings.

Original Research

Search the Turner White index to find abstracts of articles published in JCOM.

New issues are posted one month following publication of the printed journal.

View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2018, Turner White Communications
Updated 1/20/14 • jdw